Uridine
Sponsors
National Center for Research Resources (NCRR), FDA Office of Orphan Products Development, Repligen Corporation, University of Utah, Mclean Hospital
Conditions
5'-Nucleotidase SyndromeBipolar DepressionBipolar DisorderCystic FibrosisHealthy Male SubjectsManic DepressionPGM3Suicidal Ideation
Phase 1
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
CompletedNCT01261260
Start: 2006-11-30End: 2008-08-31Updated: 2010-12-16
Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation
TerminatedNCT02511041
Start: 2015-06-30End: 2017-01-24Updated: 2017-07-02
Phase 2
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
CompletedNCT00004658
Start: 1995-03-31Updated: 2005-06-24
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
CompletedNCT00322764
Start: 2006-03-31Target: 80Updated: 2007-11-09
Oral Uridine for Treatment of Bipolar Depression in Adolescents
CompletedNCT00841269
Start: 2009-05-31End: 2013-06-30Updated: 2018-03-26
Phase 4
Unknown Phase
Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
CompletedNCT00004705
Start: 1996-09-30End: 1999-01-31Updated: 2015-03-25
Uridine Adolescent Bipolar Depression Randomized Controlled Trial
CompletedNCT01805440
Start: 2013-08-31End: 2015-12-31Updated: 2018-03-12
Bioequivalence of uridine bioavailability in healthy elderly after bolus intake of oral uridine monophoshphate (UMP) versus oral uridine.
Active, not recruitingNL-OMON42055
Start: 2015-06-19Target: 25Updated: 2024-02-28